Nonsteroidal Bivalent Estrogen Ligands: An Application of the Bivalent Concept to the Estrogen Receptor

Min Shan,[†] Kathryn E. Carlson,[‡] Alexander Bujotzek,[§] Anja Wellner,[∥] Ronald Gust,[∥] Marcus Weber,[§] John A. Katzenellenbogen,[‡] and Rainer Haag*,[†]

[†]Institut für Chemie und Biochemie, Freie Universität Berlin, Takustrasse 3, 14195 Berlin, Germany
[‡]Department of Chemistry, University of Illinois at Urbana−Champaign, 600 S. Mathews Ave., Urbana, Illinois 61801, United States
[§]Zuse Institut Berlin, Takustrasse 7, 14195 Berlin, Germany
[∥]Institute of Pharmacy, Department of Pharmaceutical Chemistry, University of Innsbruck, Innrain 80/82, A-6020 Innsbruck, Austria

S *Supporting Information*

ABSTRACT: The estrogen receptor (ER) is a hormone-regulated transcription factor that binds, as a dimer, to estrogens and to specific DNA sequences. To explore at a fundamental level the geometric and topological features of bivalent-ligand binding to the ER dimer, dimeric ER crystal structures were used to rationally design nonsteroidal bivalent estrogen ligands. Guided by this structure-based ligand design, we prepared two series of bivalent ligands (agonists and antagonists) tethered by flexible spacers of varying lengths (7−47 Å) and evaluated their ER-binding affinities for the two ER subtypes and their biological activities in cell lines. Bivalent ligands based on the agonist diethylstilbestrol (DES) proved to be poor candidates, but

bivalent ligands based on the antagonist hydroxytamoxifen (OHT) were well suited for intensive study. Binding affinities of the OHT-based bivalent ligands were related to spacer length in a distinctive fashion, reaching two maximum values at 14 and 29 Å in both ER subtypes. These results demonstrate that the bivalent concept can operate in determining ER-ligand binding affinity and suggest that two distinct modes operate for the binding of bivalent estrogen ligands to the ER dimers, an *intermolecular* as well as an *intramolecular* mode. Our insights, particularly the possibility of intramolecular bivalent binding on a single ER monomer, may provide an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.

The estrogen receptor (ER) is a nuclear receptor (NR) that binds various estrogens and regulates diverse physiological and pathological activities, largely at the level of gene transcription.[1−3] Like other members of the NR superfamily, agonist binding causes a conformational change in the ER ligand binding domain (LBD) that induces receptor dimerization and results in the reorientation of the C-terminal helix (helix-12), completing the formation of a hydrophobic groove on the protein surface that is the docking site for the binding of coactivators, mediators of further transcriptional signaling.[4,5] Because estrogen action can have both beneficial and detrimental health effects, major research efforts have been devoted to developing estrogens having selective activities.

The two human ER subtypes, ERα and ERβ, have different tissue distributions and distinct as well as overlapping regulatory functions[6] and thus provide interesting targets through which ER subtype-selective ligands might provide, for example, effective menopausal hormone replacement without increasing the risk of breast cancer.[7−12] Ligands, such as tamoxifen and raloxifene (TAM and RAL, Figure 1), have been termed selective estrogen receptor modulators (SERMs)

because they display tissue-selective pharmacology, protecting bone but blocking breast cancer, presumably by exploiting differences in cellular content of coregulator proteins in different target tissues. Hydroxytamoxifen (OHT, Figure 1), an active metabolite of tamoxifen, however, causes hot flashes and increases the risk of endometrial cancer.[13]

Beyond ER subtype-selective ligands and SERMs, there are other, intriguing modes by which selective estrogens might be developed. Considerable work has gone into developing inhibitors of ER action that directly block coactivator binding,[14−16] although potent, selective agents have not yet been found. Finally, because ligand binding to the ER-LBD also induces receptor dimerization, which is essential for its transcriptional activity,[17,18] an alternative strategy for regulating ER activity is to prepare bivalent estrogen ligands that can bridge two ER-LBDs. Such bivalent ligands might bind especially well or in an unusual fashion that could affect the

Figure 1. Chemical structures of tamoxifen (TAM), hydroxytamoxifen (OHT), raloxifene (RAL), diethylstilbestrol (DES), and bivalent raloxifene ligands (BRLs).

stability of the ER dimer and alter its transcriptional activity. Consequently, they might form the basis for the design of novel agents that could provide improved tissue selectivity or endocrine therapies.

During the past two decades, several groups have studied different bivalent estrogen ligands tethered with various types of spacers, such as flexible oligomers or rigid duplex DNA, to determine the optimal spacer length for two estrogen moieties to bind simultaneously to two ER-LBDs.[19−25] Recently, we reported on bivalent raloxifene ligands (BRLs, Figure 1) tethered by oligoethylene glycol (OEG) spacers of varying length.[26] BRLs tethered by long spacers bound more weakly to ER-LBD dimers than those tethered by short spacers; the latter, short-spacer tethered BRLs, appeared to engage in _intramolecular_ bivalent binding on the same ER-LBD monomer, rather than _intermolecular_ binding between dimer pairs, a rather unexpected finding. Such a relationship between the architecture of other multivalent ligands and their ligand-protein binding mechanisms has also been observed.[27,28]

Herein, we report on bivalent ligands based on the agonist diethylstilbestrol (DES, Figure 1) and the antagonist OHT in studies designed to complement and extend our prior work on BRLs. The focus here was to examine how ER-binding affinities

and cellular activities would be affected by the agonist _versus_ antagonist nature of the ligand and the length and nature of the spacer. From our experimental and molecular modeling studies, we developed structure−activity relationships and obtained a number of insights from which we can draw instructive conclusions regarding further design of bivalent estrogen ligands. Our findings regarding the importance of ligand affinity, ER conformation, nature of the spacer, and especially our evidence that certain bivalent ligands bind to ER dimers in an intramolecular fashion—simultaneously in the cognate binding site and in the coactivator-binding groove of one ER monomer component—suggest a number of alternative strategies for preparing more selective and active ER ligands that might be useful in various endocrine therapies.

■ RESULTS AND DISCUSSION

A Thermodynamic Approach to Bivalent Ligand Design. The affinity ($K°$) of a binding event is characterized by the Gibbs free energy ($\Delta G° = -RT \ln K°$), made up of enthalpic ($\Delta H°$) and entropic components ($T\Delta S°$). Although free energy enhancement resulting from bivalent binding is attributed mostly to the entropic component,[29−31] the influence of the binding moiety on the overall binding affinity of a bivalent ligand was unknown. Whereas the standard enthalpy $\Delta H°$ and entropy $\Delta S°$ can be considered to arise from changes in the intermolecular ligand-protein binding energies and the rearrangements undergone by water during the binding, respectively,[32] one would expect that a high-affinity estrogen agonist such as DES or antagonist such as OHT would have different effects on the enthalpic component, based on their distinctive patterns of hydrogen bonding and van der Waals interactions with ER; the interactions with these ligands would likely also be different from those of RAL, the ligand used our earlier study of BRLs. Thus, a comparison between agonist and antagonist (_i.e._, DES _vs_ OHT and RAL), which have very different conformations of binding to the ER,[33−35] can help us parse out what components of bivalent ligands contribute to their binding affinity.

On the basis of thermodynamic considerations and to facilitate these comparisons, we constructed the new bivalent DES and OHT ligands using the same OEG spacers we had used for BRLs, ensuring that the spacers would have the same


Figure 2. (a) The distance between two DES molecules (spheres in green and red) bound to dimeric ERα-LBD (ribbon in gray, helix-12 in orange, coactivator in red, PDB ID 3ERD) is 30.0 Å. (b) The distance between two OHT molecules in dimeric ERα-LBD (PDB ID 3ERT) is 33.2 Å. (c) The distance between two OHT molecules bound in two cognate binding sites of dimeric ERβ-LBD (PDB ID 2FSZ) is 34.3 Å, and that between one OHT molecule bound in one cognate binding site and one OHT molecule (spheres in cyan and red) bound in the coactivator-binding groove is 16.7 Å.

conformational entropic cost, so we could ascribe a decrease or increase in the Gibbs free energy for ER binding of our new bivalent ligands to changes in enthalpy rather than entropy. Because the nonsteroidal ligands contain a double bond, they provide us with both homobivalent (*Z-Z* or *E-E* isomers) and heterobivalent (*Z-E* isomer) ligands. Since double bond geometry affects ER-binding affinity, comparisons between homo- and heterobivalent ligands offer the potential to explore and interrogate at a more general level geometric and topological features of bivalent interactions.

Studies with DES-Based Bivalent Ligands. *DES-Based Ligand Design.* The structure of the ERα-LBD dimer bound to two DES molecules (PDB ID 3ERD) was modeled using PyMOL (Figure 2a). The closest distance between two DES molecules at carbon 1 of the stilbene structure is 30.0 Å. As an ER agonist, DES binds deeply in the hydrophobic cognate binding site, and the direct path between ligands passes through portions of protein. Thus, a spacer would need to be longer than 30 Å to adopt a nonlinear pathway avoiding steric obstruction by the protein.

As previously, we chose OEG spacers of 39.5−46.7 Å length (EG$_{10}$ to EG$_{12}$, approximately 10 Å longer than the calculated distance) to tether two DES moieties *via* an amide link, producing bivalent ligands with the potential for intermolecular bivalent binding between two cognate binding sites in the ER dimer (Figure 3, **1**−**3**). Moreover, to minimize the folding and

conformational entropic cost of the OEG spacer, two carbon-hybrid OEG spacers and one biphenyl-hybrid OEG spacer, with extended lengths of 34.8−39.8 Å, were chosen (**4**−**6**, Figure 3). In addition, a bivalent DES ligand (**7**) tethered by a much shorter 1,2-diethoxyethylene spacer (EG$_2$, 10.8 Å, Figure 3) and three monovalent DES ligands (**8**−**10**, Figure 3) were also prepared. Because the geometric isomers of DES bind with different affinities, separation of the low-binding *Z*-isomer from the desired high-binding *E*-isomer was performed.[36]

DES-Based Ligand ER-Binding Affinity. Binding affinities of *E-E* isomers of mono- and bivalent DES ligands (**1**−**10**) were evaluated by radiometric binding assays,[37,38] using full-length human ERα and ERβ, with [^{3}H]-E$_2$ as tracer and E$_2$ as standard. They are expressed as relative binding affinity (RBA) values, relative to that of E$_2$ (RBA = 100%; Table 1). The affinities of ligands **1**−**10**, except for DES itself, were considerably lower than E$_2$. Among ligands **1**−**6**, ligand **2** tethered by a 43.1 Å OEG spacer had the highest affinity, which however was 10-fold lower than that of ligand **7**, tethered by a 10.8 Å spacer on both ER subtypes.

The low affinities of bivalent DES ligands suggest two things: (1) Introduction of a polar group (carboxylic acid, ester, or amide, **8**−**10**) onto the hydrophobic core of DES dramatically reduces ER-binding affinity, presumably because of the hydrophobic character of the binding pocket.[12,39] (2) Agonist ligands, such as DES and E$_2$, stabilize an ER-LBD conformation with ligand fully encapsulated by protein, with no obvious way for a tethering group to exit the fully enclosed pocket, making it particularly challenging to create bivalent estrogens based on agonist ligands.

DES-Based Ligand Biological Activity. Since RBA values do not reflect biological effects, the *E-E* isomers of bivalent DES ligands **1**−**7** were evaluated for their hormonal activities on ERα and ERβ-regulated reporter genes using U2OS cells transiently transfected with ER expression plasmids pSG5-ERα (U2OS/ERα) or pSG5-ERβ FL (U2OS/ERβ) and the reporter plasmid p(ERE)2-luc+ (Table 2).[26] The intrinsic activity (IA) of each ligand was assayed at 10 μM. Ligands **1**−**7** showed pure agonistic activity that was related to spacer length: ligands **1** and **4**−**6** with spacer lengths of 34.8−39.8 Å had less than 50% IA values on ERα, whereas on ERβ only ligands **1** and **5** have

Figure 3. Chemical structures of *E*- and *E-E* isomers of mono- and bivalent DES ligands **1**−**10**.

Table 1. Spacer Structures, Maximum Lengths, and Relative Binding Affinity (RBA) Values of Mono- and Bivalent DES Ligands 1−10

entry	ligand	spacer structure	max length[a] [Å]	RBA for ERα [%]	RBA for ERβ [%]
1	**1**[b]	EG$_{10}$	39.5	0.012 ± 0.001	0.039 ± 0.011
2	**2**[b]	EG$_{11}$	43.1	0.021 ± 0.005	0.048 ± 0.004
3	**3**[b]	EG$_{12}$	46.7	0.012 ± 0.003	0.023 ± 0.006
4	**4**[b]	EG$_4$C$_4$EG$_4$	34.8	0.006 ± 0.001	0.013 ± 0.004
5	**5**[b]	EG$_4$C$_8$EG$_4$	39.8	0.013 ± 0.002	0.022 ± 0.002
6	**6**[b]	EG$_4$Ph$_2$EG$_4$	39.0	0.008 ± 0.002	0.020 ± 0.006
7	**6**[c]	EG$_4$Ph$_2$EG$_4$	39.0	0.003 ± 0.001	0.008 ± 0.000
8	**7**[d]	EG$_2$	10.8	0.230 ± 0.005	0.247 ± 0.026
9	**8**[e]	monovalent		0.067 ± 0.004	0.159 ± 0.004
10	**9**[e]	monovalent		7.87 ± 1.9	41.98 ± 6.7
11	**10**[e]	monovalent		0.011 ± 0.002	0.051 ± 0.011
12	DES	monovalent		372 ± 106[f]	278 ± 54[f]

[a]Extended spacer length between two nitrogen atoms measured by using PyMOL. [b]Pure *E-E* isomer was evaluated in assays. [c]Pure *E-Z* isomer was evaluated in assays. [d]The ER-binding affinity of bivalent DES ligand **7** was evaluated on the basis of 60% *E-E* isomer. [e]The ER-binding affinities of monovalent ligands **8**−**10** were evaluated on the basis of 80% *E*-isomer. [f]Reference 39.

Table 2. Hormonal Activity and Growth Inhibition of Mono- and Bivalent DES Ligands (1−7)

| entry | ligand | hormonal activity (U2OS cells)[a] | | | | growth inhibition | |
| | | ERα | | ERβ | | IC$_{50}$ after 96 h [μM] | |
		IA[b] [%]	CD[c] [%]	IA[b] [%]	CD[c] [%]	MCF-7	MDA-MB-231
1	**1**[d]	49	93	50	96	7.3	5.4
2	**2**[d]	79	95	104	92	9.0	9.1
3	**3**[d]	81	93	89	91	5.1	5.6
4	**4**[d]	22	86	58	86	5.5	4.9
5	**5**[d]	22	78	32	77	1.8	1.2
6	**6**[d]	33	88	89	85	<0.63	>20
7	**6**[e]	−7	80	55	90	<0.63	>20
8	**7**[f]	90	93	95	92	6.5	5.6
9	DES[g]	105	103	111	90	5.9	4.3

[a]Concentration of **1**−**7** was 10 μM. [b]Intrinsic activity (IA). [c]Cell density (CD). [d]Pure Z-Z isomer. [e]Pure E-Z isomer. [f]The bivalent DES ligand **7** was evaluated based on 60% E-E isomer. [g]The concentration was 10 nM.

similar IA values. Cell density was used to evaluate cytotoxic effects, and none of these ligands influenced U2OS cell growth.

In further evaluation of growth inhibitory effects in ER-positive (MCF-7) and ER-negative (MDA-MB-231) cell lines,[26] IC$_{50}$ values were calculated from concentration-dependent Treated/Control$_{corr}$ (T/C_{corr} [%]) values after a 96-h incubation (Table 2). ER agonists often show non-ER-mediated growth inhibition at high concentrations, exemplified by monovalent DES having an IC$_{50}$ value of 5 μM for both cell lines, and most bivalent ligands showed similar, non-ER dependent growth suppression. Ligand **6** (E-E isomer) was an exception, showing unusual cell-line-dependent effects, being completely inactive in ER-negative cells (IC$_{50}$ > 20 μM) but rather potent in ER-positive cells (IC$_{50}$ < 0.63 μM). Remarkably, despite its low binding affinity (0.003%) for ERα, the E-Z isomer of ligand **6** showed identical growth suppression as its E-E isomer in both cells.

A possible explanation for the more potent growth suppression of ER-positive cells by ligand **6** lies in its unique spacer structure, the biphenyl segment; it might be interrupting ER signaling by a different mechanism, namely, a hydrophobic-driven interaction between the bis-arene and the coactivator-binding site of ERα. In this manner, ER signaling in support of cell proliferation would be inhibited in ER-positive but not ER-negative cells. Certain biphenyl systems are known to function as inhibitors of coactivator-binding, suggesting that this alternate mode of inhibition by ligand **6** is feasible.[40] In summary, the effects of these ligands mirrored that of the parent DES ligand: they were mostly pure agonists and did not show any ER-dependent suppression of cell growth.

Studies with OHT-Based Bivalent Ligands. *OHT-Based Ligand Design.* Unlike ER agonists, the structures of ER bound to OHT are enlarged in the 11β direction to accommodate the bulky side chain. This local remodeling provides the OHT molecule access to the exterior of the ER, where the basic amino group forms a salt bridge with a surface aspartic acid (Asp351 ERα; Asp303 ERβ).[34,35] This amino group, positioned at the protein surface, offers a promising site through which to tether the OHT moieties. To rationally design bivalent OHT ligands, computer modeling of dimeric ER-LBD crystal structures bound to OHT (PDB ID 3ERT for ERα and 2FSZ for ERβ) was performed using PyMOL. We found that

the closest distance between two nitrogen atoms in the crystal structure is 33.2 and 34.3 Å for ERα and ERβ, respectively (Figure 2b,c).

Notably, there are four OHT molecules in the dimeric ERβ-LBD crystal structure, two in the cognate binding sites and the other two in the hydrophobic coactivator-binding grooves on the protein surface.[41] The distance between the nitrogen atom of one OHT molecule in the cognate binding site and the nitrogen atom of the other OHT molecule in the coactivator-binding groove on the same monomer component is much less, only 16.7 Å.

To further understand the intra- *vs* intermolecular bivalent binding relationship with bivalent OHT ligands, we prepared nine bivalent OHT ligands **11**−**19** (Figure 4) tethered through

Figure 4. Chemical structures of mono- and bivalent OHT ligands **11**−**20**.

the amino groups by nine OEG spacers, with spacer lengths, 7.24−43.1 Å, sufficient to span either intra- or intermolecular bivalent binding. Additionally, one monovalent OHT ligand **20** (Figure 4) with a side chain was prepared as a control. The stereochemistry of OHT molecules affects ER-ligand binding: Z-OHT is an antagonist with a 3-fold higher affinity than E$_2$, whereas E-OHT is an agonist with only 5% the affinity of E$_2$.[42] As with DES ligands, geometric isomerization of OHT-based ligands means that separations need to be performed carefully.[43]

OHT-Based Ligand ER-Binding Affinity. The eight bivalent ligands (**11**−**17** and **19**) evaluated are of two types: (1) homobivalent ligands—both OHT moieties are high affinity Z-isomers, and (2) heterobivalent ligands—one Z-OHT moiety tethered to one low affinity E-OHT moiety. Because heterobivalent ligands (Z-E isomers) have essentially the same lipophilicity as homobivalent ligands (Z-Z isomers), the binding of heterobivalent ligands can be considered as bivalent controls for specific *versus* nonspecific effects of binding to the second site. Both isomers of the monovalent control **20** were evaluated; binding affinities are expressed as RBA values (Table 3).

Generally, binding affinities of bivalent OHT ligands are only somewhat lower than that of E$_2$, with ERα higher than ERβ. Thus, the amino link and the OEG spacer are tolerated by the cognate binding site. The monovalent ligand **20Z** also had a much higher binding affinity than its E-isomer **20E**. The Z-Z isomers (**13**−**16**) had overall stronger ER-binding affinities than the Z-E isomers on ERβ but not ERα, indicating that stereochemistry plays a variable role in second-site ER-binding.

Figure 5 illustrates the relationship between RBA values and spacer lengths of the bivalent OHT ligands: affinities peaked at

Table 3. Spacer Structures, Maximum Lengths, and Relative Binding Affinity (RBA) Values of Mono- and Bivalent OHT Ligands (11−20)

entry	ligand	spacer structure	max length[a] [Å]	homobivalent ligand (Z-Z/Z isomer)		heterobivalent ligand (Z-E/E isomer)	
				ERα	ERβ	ERα	ERβ
1	**11**	EG$_1$	7.24	13.8 ± 4.3	6.11 ± 1.4	6.60 ± 0.5	3.44 ± 0.7
2	**12**	EG$_2$	10.8	16.4 ± 2.1	5.55 ± 1.3	23.5 ± 5.2	6.25 ± 0.6
3	**13**	EG$_3$	14.4	37.2 ± 2.3	13.9 ± 3.4	8.16 ± 2.0	9.57 ± 1.8
4	**14**	EG$_4$	18.0	14.9 ± 4.0	12.2 ± 2.1	13.6 ± 1.3	4.77 ± 1.5
5	**15**	EG$_5$	21.6	20.8 ± 5.5	12.8 ± 2.0	10.9 ± 2.3	3.20 ± 1.0
6	**16**	EG$_7$	28.8	30.7 ± 2.8	20.7 ± 1.6	32.3 ± 8.1	9.48 ± 1.4
7	**17**	EG$_9$	35.9	28.1 ± 3.7	7.92 ± 1.5	23.9 ± 6.9	7.85 ± 2.0
8	**18**[b]	EG$_{10}$	39.5	17.2 ± 2.0[b]	9.53 ± 2.4[b]		
9	**19**	EG$_{11}$	43.1	27.9 ± 4.0	7.17 ± 1.4	18.0 ± 5.0	7.60 ± 2.2
10	**19**[b]	EG$_{11}$	43.1	21.8 ± 3.1[b]	9.75 ± 0.57[b]		
11	**20**	monovalent	19.2[c]	78.1 ± 12	34.2 ± 1.7	12.4 ± 2.2	8.03 ± 0.01
12	OHT	monovalent		285[d]	62[e]	5[d]	

[a]Extended spacer length between two nitrogen atoms measured by using PyMOL. [b]The ER-binding affinities for bivalent OHT ligands **18** and **19** were evaluated based on Z-Z:Z-E:E-E = 1:2:1 isomers according to analytical RP-HPLC analyses. [c]Maximum extended side chain length of EG$_5$Me. [d]Reference 42. [e]Reference 44.

Figure 5. Relationship between relative binding affinity (RBA) values of mono- and bivalent OHT ligands (**11−17**, **19**, and **20**) in both ER subtypes and their maximum spacer lengths.

14.4 and 28.8 Å (EG$_3$ and EG$_7$, respectively) in both subtypes. This is not only consistent with our previous interpretation of *intra- vs intermolecular* binding modes of BRLs[26] but also precise enough to provide spacer-length information for each binding mode. Interestingly, **11ZZ**, tethered by a 7.24 Å spacer (EG$_1$), did not reach a maximum like the BRL with a 4.71 Å spacer,[26] whereas ligand **13ZZ**, tethered by a longer 14.4 Å spacer, peaked on both ER subtypes. This distinction suggests that the Z-OHT moiety binds to a different secondary site in ERα than did the RAL moiety. Thus, intramolecular bivalent binding can be achieved by the longer spacer of ligand **13ZZ**. Moreover, the affinity difference between **13ZZ** and **13ZE** on ERα (37.2% *vs* 8.16%) is greater than that on ERβ (13.9% *vs* 9.57%), suggesting that the stereochemical tolerance of this secondary site on ERα is lower than on ERβ. Furthermore, ligand **12ZE** tethered by a 10.8 Å-long spacer (EG$_2$) also reached a maximum binding peak on ERα, suggesting the E-

OHT moiety can bind to a different secondary site, whereas the Z-OHT moiety cannot.

A second maximum binding peak was reached by ligand **16** tethered by a 28.8 Å-long spacer (EG$_7$) on both subtypes, consistent with intermolecular bivalent binding between two ER cognate binding sites. It is challenging to rationalize why ER-binding affinities of **16ZZ** and **16ZE** on the ERα were nearly identical (30.7% *vs* 32.3%), but the stereochemical tolerance at the second binding site might be rather low, so once one Z-OHT moiety binds in the cognate binding site of one monomer, the lipophilic nature of the second OHT moiety, rather than its Z/E stereochemistry, determines its ability either to bind to the second cognate binding site or elsewhere on the ERα surface. While the secondary site involved in intramolecular bivalent binding, the coactivator-binding groove, is precedented in the ERβ structure, the location of a noncognate site for intermolecular bivalent binding cannot be ascertained with certainty.

In contrast to ERα, affinity differences between **16ZZ** and **16ZE** on ERβ (20.7% vs 9.48%) were larger, suggesting that the ERβ subtype is more stereochemically discriminating in binding the second OHT moiety. Remarkably, a gradual decrease in affinity with increasing spacer length (**16ZZ–18ZZ**) on ERα but not on ERβ revealed that intermolecular bivalent binding could still be achieved with spacers longer than 28.8 Å on the ERα, whereas on the ERβ it peaked sharply with a 28.8 Å spacer. This may reflect that the ERα cognate binding site is approximately 100 Å^3 larger than ERβ.[12]

OHT-Based Ligand Biological Activity. Because of cytotoxicity, we could not evaluate the biological activity of the OHT-based ligands (**11–17, 19,** and **20**) in U2OS cells using the ER-regulated reporter genes used earlier for the DES ligands. Thus, their growth inhibitory effects were evaluated with MCF-7 and MDA-MB-231 cells (Table 4).

Table 4. Hormonal Activity and Growth Inhibition of Mono- and Bivalent OHT Ligands (11−17, 19, and 20)

| | | hormonal activity (U2OS cells)[a] | | | | growth inhibition | |
| | | ERα | | ERβ | | IC$_{50}$ after 96 h [μM] | |
entry	ligand	IA[b] [%]	CD[c] [%]	IA[b] [%]	CD[c] [%]	MCF7	MDA-MB-231
1	**11ZZ**	−71	81	−91	79	0.11	>20
2	**12ZZ**	−64	80	−89	78	0.07	1.84
3	**13ZZ**	−83	51	−93	55	0.11	1.95
4	**14ZZ**	−85	61	−96	59	0.06	1.23
5	**15ZZ**	−95	15	−99	15	0.08	1.20
6	**16ZZ**	−100	10	−99	9	0.10	0.69
7	**17ZZ**	−100	9	−100	8	2.10	13.98
8	**19ZZ**	−100	8	−100	7	0.01	0.32
9	**19**[d]	−99	8	−100	6	0.15	0.32
10	**20Z**	−42		−77		0.37	2.17
11	**20E**					0.40	1.94
12	OHT[e]	5	110	−47	92	0.15	4.59

[a]Concentration 10 μM. [b]Intrinsic activity (IA). [c]Cell density (CD). [d]Cell assays were evaluated based on *Z-Z:Z-E:E-E* = 1:2:1 isomers. [e]The concentration was 1 μM.

All the *Z-Z* isomers (except **17ZZ**) were potent growth inhibitors of MCF-7 cells (IC$_{50}$ ≤ 0.11 μM). Notably, these bivalent ligands were more potent than the monovalent control **20Z** (entry 10) or OHT itself (entry 12). The potency advantage of bivalent ligands compared to monovalent control **20Z** and OHT is especially important, because it suggests that bivalent binding can significantly enhance activity. The growth inhibitory effects of all ligands is also higher in the ER-positive cells, with MDA-MB-231/MCF-7 potency ratios ranging from 7 (**16ZZ**, entry 6) to 32 (**19ZZ**, entry 8). The *Z-Z* isomer of ligand **19ZZ** was the most potent in both cell lines, while the growth inhibition of its *Z-E* isomer (entry 9) was 15-fold weaker in ER-positive cells. By contrast, the monovalent controls **20Z** and **20E** had rather similar growth inhibitory potencies in both cell lines (entries 10 and 11).

While growth suppression of ER-positive cells can be attributed to the antagonist activity of bivalent OHT ligands, growth inhibition in ER-negative cells is significant and suggests that the cytotoxicity of the bivalent OHT ligands may be a combination of ER-dependent and ER-independent effects.

Computer Modeling. *ERβ Complex with Ligand 13ZZ and Ligand 12ZE.* The binding mode of the second OHT moiety in the ERβ coactivator-binding groove is known from a crystal structure (Figure 2c). Our binding mode for ligand **13ZZ**, predicted by modeling, allows for interaction with the same residues as in the crystal structure (PDB ID 2FSZ), although the OHT moiety in the coactivator-binding groove adopts a reversed orientation, where the nitrogen atom connected to the spacer points toward the cognate binding site (Figure 6a), with the ethyl group protruding outward into solvent.

Ligand **12ZE** is equally able to form interactions with the coactivator-binding groove, provided the spacer adopts an extended conformation, but the *E*-OHT moiety is less well accommodated in the coactivator-binding groove, because now the phenyl group from the outside OHT protrudes into solvent (Figure 6b). Thus, a better accommodation of this outside OHT moiety in the coactivator-binding groove may have been hindered by its short spacer, as is consistent with the RBA measurements.

ERα Complex with Ligand 13ZZ and Ligand 12ZE. Because the topology of the coactivator-binding groove for the second OHT moiety is dependent on the position of helix-12, which in turn is dependent on the activation state of ERα, prediction of ERα binding modes at the coactivator-binding groove is complicated. Using structural knowledge on ERβ coactivator-site binding modes, we could obtain a stable binding mode for ligand **13ZZ** that interacted with key residues of the groove and helix-12 (Figure 6c). The model suggests that helix-12 performs a slight shift due to interactions between the *Z*-OHT moiety and the coactivator-binding groove, while enclosing it as a binding site with multiple interactions. Interestingly, we could not find a stable binding mode for ligand **12ZE**. The EG$_2$ spacer is insufficient to enable good intramolecular binding with ERα, and the outside *E*-OHT moiety flipped over, forming nonspecific interactions with other residues on the ERα surface.

ERα and ERβ Complexes with Ligand 16ZZ. By modeling ligand **16ZZ** into the cognate binding sites of ERα and ERβ (Figure 6d,e), we found that it could bridge between both of them in an intermolecular bivalent binding fashion. The *Z*-OHT moieties were slightly shifted compared to the monovalent OHT in the crystal structure, possibly due to minor rearrangements during the simulation or constraints from the attached spacer that distort the ideal arrangement of the *Z*-OHT moieties in the cognate binding site.

Summary and Conclusion. *Intermolecular and Intramolecular Modes of Bivalent Binding and Unusual Biological Activity in Cell.* We have prepared two series of bivalent estrogen ligands tethered by OEG spacers of varying lengths (7.24−46.7 Å) and evaluated their binding affinities and biological properties. Previously, several different types of spacers (*e.g.*, flexible oligomers and rigid duplex DNA) were used to tether various estrogen binding moieties. Compared to rigid spacers, an oligomer such as OEG has the advantage of high flexibility to avoid steric clashes with proteins. We found two peaks of binding affinity with bivalent OHT ligands tethered with 14.4 and 28.8 Å spacers, which on the basis of our modeling efforts correspond to the intra- and intermolecular bivalent ER-binding modes, respectively. Most notably, many bivalent OHT ligands are potent growth inhibitors of MCF-7 cells; they are more potent on ER-positive than ER-negative cells and more potent than the monovalent control and OHT itself. Thus, bivalent OHT ligands exhibit some unusual biological activities in ER-positive cells, although it is less

Figure 6. (a) Ligand **13ZZ** (sticks in green and red) in complex with ERβ-LBD (ribbon in gray). (b) Ligand **12ZE** in complex with ERβ-LBD. (c) Ligand **13ZZ** in complex with ERα-LBD. (d) Ligand **16ZZ** in complex with ERα-LBD. (e) Ligand **16ZZ** in complex with ERβ-LBD. Results based on a 10 ns simulation in explicit water. An overlay with OHT from crystal structure is shown in purple.

clear how growth inhibitory potency correlates with binding affinity and apparent bivalent binding behavior.

Global Observations on Bivalent Ligand Design. On the basis of our results and those of others,[19−26] we can reach a number of conclusions regarding factors that influence bivalent ER-ligand interaction. First, an estrogen antagonist (*e.g.*, RAL or OHT) induces an antagonistic ER-binding conformation, where the displacement of helix-12 creates a channel through which certain substituents can escape the confines of the cognate binding site in the direction of the ER dimer interface. By contrast, a substituent on an estrogen agonist has difficulty in getting access to the protein exterior unless it is at the 17α position of the steroidal structure;[33,45] however, a spacer extending from this site is directed away from the dimer interface.[23] Notably, the bivalent ethynyl estradiol (EE$_2$) ligands prepared by LaFrate *et al.*[23] had better ER-binding affinity than bivalent E$_2$ ligands tethered elsewhere.[21,22] Second, the functional group through which the spacer is linked to the ligand needs to be compatible with the environment of the bound ligand. Thus, introduction of a polar amide at C1 of the DES ligands dramatically reduced their affinity; by contrast, the tertiary amine in bivalent OHT ligands maintained salt bridge interactions with protein residues and gave them higher affinities. Third, a high-affinity estrogen antagonist such as OHT gave bivalent ligands with higher affinity than BRLs studied earlier,[26] attributed to a more negative enthalpy caused by OHT binding to the ER. Fourth, use of a rigid central element[29,46] can help to minimize the conformational entropy loss and enhance the binding affinity, as noted by bivalent estrogens tethered by rigid duplex DNA, studied previously.[25] While avoiding intramolecular hydrophobic interactions between spacer units like the biphenyl segment and DES moieties,[47] it is also good to avoid additional mechanisms of activity, unless a coactivator-binding inhibition is desired. Finally, flexible spacers can have conformational biases; *e.g.*, OEGs form helical coils because of their preferred gauche orientation.[48] Spanning the same distance with more flexible oligomers, such as oligopropylene and oligobutylene glycols, might raise binding affinities.[49]

Consideration of Heterofunctional Bivalent Ligand Design. The good evidence for *intramolecular* ER-binding we provide suggests that even better bivalent ligands might be designed by explicitly optimizing their heterofunctional nature, *i.e.*, one binding moiety optimized for the cognate binding site and the other for the coactivator-binding groove (or at other secondary sites on the same monomer). Presently most coactivator inhibitors designed on the basis of the LXXLL binding motif or found by high throughput screening have only micromolar activities, leaving a need for developing high-affinity ligands for this site.[14−16,50] Nevertheless, our finding of the intramolecular bivalent binding mode suggests tantalizing new opportunities for the design of novel heterofunctional bivalent ligands as an alternative strategy to create more active and selective estrogens.

■ METHODS

Chemical preparations, characterizations, biological evaluations, and computer modeling of mono/bivalent ligands (**1−20**) are provided in Supporting Information. Cellular assays were performed according to the previous report.[26]

■ ASSOCIATED CONTENT

Ⓢ Supporting Information
This material is free *via* the Internet at http://pubs.acs.org.

■ AUTHOR INFORMATION

Corresponding Author
*E-mail: haag@chemie.fu-berlin.de.
Notes
The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

REFERENCES

(1) Avendaño, C., and Menéndez, J. C. (2008) Anticancer Drugs That Inhibit Hormone Action. In *Medicinal Chemistry of Anticancer Drugs*, pp 53−92, Elsevier, Amsterdam.

(2) Weatherman, R. V. (2008) Untangling the Estrogen Receptor Web: Tools to Selectively Study Estrogen-binding Receptors. In *Nuclear Receptors as Drug Targets* (Ottow, E. and Weinmann, H., Eds.), pp 47−64, Wiley-VCH, Weinheim.

(3) Jordan, V. C., and Furr, B. J. A. (2002) An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer. In *Hormone Therapy in Breast and Prostate Cancer*, pp 1−14, Humana Press, Totowa.

(4) Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) The nuclear receptor superfamily: The second decade. *Cell 83*, 835−839.

(5) Olefsky, J. M. (2001) Nuclear receptor minireview series. *J. Biol. Chem. 276*, 36863−36864.

(6) Couse, J. F., Lindzey, J., Grandien, K., Gustafsson, J. A., and Korach, K. S. (1997) Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ER alpha-knockout mouse. *Endocrinology 138*, 4613−4621.

(7) Grese, T. A., Sluka, J. P., Bryant, H. U., Cullinan, G. J., Glasebrook, A. L., Jones, C. D., Matsumoto, K., Palkowitz, A. D., Sato, M., Termine, J. D., Winter, M. A., Yang, N. N., and Dodge, J. A. (1997) Molecular determinants of tissue selectivity in estrogen receptor modulators. *Proc. Natl. Acad. Sci. U.S.A. 94*, 14105−14110.

(8) Jordan, V. C. (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. *J. Med. Chem. 46*, 883−908.

(9) Jordan, V. C. (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. *J. Med. Chem. 46*, 1081−1111.

(10) Minutolo, F., Macchia, M., Katzenellenbogen, B. S., and Katzenellenbogen, J. A. (2011) Estrogen receptor β ligands: Recent advances and biomedical applications. *Med. Res. Rev. 31*, 364−442.

(11) Bertini, S., De Cupertinis, A., Granchi, C., Bargagli, B., Tuccinardi, T., Martinelli, A., Macchia, M., Gunther, J. R., Carlson, K. E., Katzenellenbogen, J. A., and Minutolo, F. (2011) Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes. *Eur. J. Med. Chem. 46*, 2453−2462.

(12) Katzenellenbogen, J. A. (2011) The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: Addressing the "Core Issue" in the Design of Estrogen Receptor Ligands. *J. Med. Chem. 54*, 5271−5282.

(13) Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J. Natl. Cancer Inst. 90*, 1371−1388.

(14) Parent, A. A., Gunther, J. R., and Katzenellenbogen, J. A. (2008) Blocking estrogen signaling after the hormone: Pyrimidine-core inhibitors of estrogen receptor-coactivator binding. *J. Med. Chem. 51*, 6512−6530.

(15) Gunther, J. R., Moore, T. W., Cottins, M. L., and Katzenellenbogen, J. A. (2008) Amphipathic benzenes are designed inhibitors of the estrogen receptor α/steroid receptor coactivator interaction. *ACS Chem. Biol. 3*, 282−286.

(16) Phillips, C., Roberts, L. R., Schade, M., Bazin, R., Bent, A., Davies, N. L., Moore, R., Pannifer, A. D., Pickford, A. R., Prior, S. H., Read, C. M., Scott, A., Brown, D. G., Xu, B., and Irving, S. L. (2011) Design and structure of stapled peptides binding to estrogen receptors. *J. Am. Chem. Soc. 133*, 9696−9699.

(17) Brandt, M. E., and Vickery, L. E. (1997) Cooperativity and dimerization of recombinant human estrogen receptor hormone-binding domain. *J. Biol. Chem. 272*, 4843−4849.

(18) Tamrazi, A., Carlson, K. E., Daniels, J. R., Hurth, K. M., and Katzenellenbogen, J. A. (2002) Estrogen receptor dimerization: Ligand binding regulates dimer affinity and dimer dissociation rate. *Mol. Endocrinol. 16*, 2706−2719.

(19) Bergmann, K. E., Wooge, C. H., Carlson, K. E., Katzenellenbogen, B. S., and Katzenellenbogen, J. A. (1994) Bivalent ligands as probes of estrogen-receptor action. *J. Steroid Biochem. Mol. Biol. 49*, 139−152.

(20) Groleau, S., Nault, J., Lepage, M., Couture, M., Dallaire, N., Bérubé, G., and Gaudreault, R. C. (1999) Synthesis and preliminary in vitro cytotoxic activity of new triphenylethylene dimers. *Bioorg. Chem. 27*, 383−394.

(21) Rabouin, D., Perron, V., N'Zemba, B., Gaudreault, R. C., and Bérubé, G. (2003) A facile synthesis of C_2-symmetric 17β-estradiol dimers. *Bioorg. Med. Chem. Lett. 13*, 557−560.

(22) Bérubé, G., Rabouina, D., Perron, V., N'Zemba, B., Gaudreault, R. C., Parenta, S., and Asselin, E. E. (2006) Synthesis of unique 17β-estradiol homo-dimers, estrogen receptors binding affinity evaluation and cytocidal activity on breast, intestinal and skin cancer cell lines. *Steroids 71*, 911−921.

(23) LaFrate, A. L., Carlson, K. E., and Katzenellenbogen, J. A. (2009) Steroidal bivalent ligands for the estrogen receptor: Design, synthesis, characterization and binding affinities. *Bioorg. Med. Chem. 17*, 3528−3535.

(24) Wendlandt, A. E., Yelton, S. M., Lou, D. Y., Watt, D. S., and Noonan, D. J. (2010) Synthesis and functional analysis of novel bivalent estrogens. *Steroids 75*, 825−833.

(25) Abendroth, F., Bujotzek, A., Shan, M., Haag, R., Weber, M., and Seitz, O. (2011) DNA-controlled bivalent presentation of ligands for the estrogen receptor. *Angew. Chem., Int. Ed. 50*, 8592−8596.

(26) Shan, M., Bujotzek, A., Abendroth, F., Wellner, A., Gust, R., Seitz, O., Weber, M., and Haag, R. (2011) Conformational analysis of bivalent estrogen receptor ligands: From intramolecular to inter-molecular binding. *ChemBioChem 12*, 2587−2598.

(27) Bertozzi, C. R., and Kiessling, L. L. (2001) Chemical glycobiology. *Science 291*, 2357−2364.

(28) Gestwicki, J. E., Cairo, C. W., Strong, L. E., Oetjen, K. A., and Kiessling, L. L. (2002) Influencing receptor-ligand binding mecha-nisms with multivalent ligand architecture. *J. Am. Chem. Soc. 124*, 14922−14933.

(29) Mammen, M., Choi, S. K., and Whitesides, G. M. (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. *Angew. Chem., Int. Ed. 37*, 2754−2794.

(30) Kiessling, L. L., Gestwicki, J. E., and Strong, L. E. (2006) Synthetic multivalent ligands as probes of signal transduction. *Angew. Chem., Int. Ed. 45*, 2348−2368.

(31) Schwefel, D., Maierhofer, C., Beck, J. G., Seeberger, S., Diederichs, K., Möller, H. M., Welte, W., and Wittmann, V. (2010) Structural basis of multivalent binding to wheat germ agglutinin. *J. Am. Chem. Soc. 132*, 8704−8719.

(32) Testa, B., Jenner, P., Kilpatrick, G. J., Eltayar, N., Vandewaterbeemd, H., and Marsden, C. D. (1987) Do Thermody-namic studies provide information on both the binding to and the activation of dopaminergic and other receptors. *Biochem. Pharmacol. 36*, 4041−4046.

(33) Nettles, K. W., Bruning, J. B., Gil, G., O'Neill, E. E., Nowak, J., Guo, Y., Kim, Y., DeSombre, E. R., Dilis, R., Hanson, R. N., Joachimiak, A., and Greene, G. L. (2007) Structural plasticity in the oestrogen receptor ligand-binding domain. *EMBO Rep. 8*, 563−568.

(34) Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell 95*, 927−937.

(35) Pike, A. C. W., Brzozowski, A. M., Hubbard, R. E., Bonn, T., Thorsell, A. G., Engstrom, O., Ljunggren, J., Gustafsson, J. K., and Carlquist, M. (1999) Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. *EMBO J. 18*, 4608−4618.

(36) Winkler, V. W., Nyman, M. A., and Egan, R. S. (1971) Diethylstilbestrol cis-trans isomerization and estrogen activity of diethylstilbestrol isomers. *Steroids 17*, 197−207.

(37) Katzenellenbogen, J. A., Johnson, H. J., and Myers, H. N. (1973) Photoaffinity labels for estrogen binding proteins of rat uterus. *Biochemistry 12*, 4085−4092.

(38) Carlson, K. E., Choi, I., Gee, A., Katzenellenbogen, B. S., and Katzenellenbogen, J. A. (1997) Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: Evidence that an open pocket conformation is required for ligand interaction. *Biochemistry 36*, 14897−14905.

(39) Waibel, M., De Angelis, M., Stossi, F., Kieser, K. J., Carlson, K. E., Katzenellenbogen, B. S., and Katzenellenbogen, J. A. (2009) Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta. *Eur. J. Med. Chem. 44*, 3412−3424.

(40) Williams, A. B., Weiser, P. T., Hanson, R. N., Gunther, J, R., and Katzenellenbogen, J. A. (2009) Synthesis of biphenyl proteomimetics as estrogen receptor-α coactivator binding inhibitors. *Org. Lett. 11*, 5370−5373.

(41) Wang, Y., Chirgadze, N. Y., Briggs, S. L., Khan, S., Jensen, E. V., and Burris, T. P. (2006) A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor β. *Proc. Natl. Acad. Sci. U.S.A. 103*, 9908−9911.

(42) Robertson, D. W., Katzenellenbogen, J. A., Long, D. J., Rorke, E. A., and Katzenellenbogen, B. S. (1982) Tamoxifen anti-estrogens - a comparison of the activity, pharmacokinetics, and metabolic-activation of the cis-isomer and trans-isomer of tamoxifen. *J. Steroid Biochem. Mol. Biol. 16*, 1−13.

(43) Katzenellenbogen, J. A., Carlson, K. E., and Katzenellenbogen, B. S. (1985) Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. *J. Steroid Biochem. 22*, 589−596.

(44) Kim, S., and Katzenellenbogen, J. A. (2000) Triarylethylene bisphenols with a novel cycle are ligands for the estrogen receptor. *Bioorg. Med. Chem. 8*, 785−793.

(45) Li, M. J., Greenblatt, H. M., Dym, O., Albeck, S., Pais, A., Gunanathan, C., Milstein, D., Degani, H., and Sussman, J. L. (2011) Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of selective estrogen receptor modulators. *J. Med. Chem. 54*, 3575−3580.

(46) Krishnamurthy, V. M., Estroff, L. A., and Whitesides, G. M. (2006) Multivalency in Ligand Design. In *Fragment-based Approaches in Drug Discovery* (Jahnke, W. and Erlanson, D. A., Eds.), pp 11−54, Wiley-VCH, Weinheim.

(47) Bujotzek, A., Shan, M., Haag, R., and Weber, M. (2011) Towards a rational spacer design for bivalent inhibition of estrogen receptor. *J. Comput. Aided Mol. Des. 25*, 253−262.

(48) Kjellander, R., and Florin, E. (1981) Water structure and changes in thermal stability of the system poly(ethylene oxide)-water. *J. Chem. Soc., Faraday Trans. 1 77*, 2053−2077.

(49) LaFrate, A. L. (2008) Bivalent Ligands for the Estrogen Receptor. In *Synthesis and Biological Evaluation of Coactivator Binding Inhibitors and Bivalent Ligands for the Estrogen Receptor*, pp 60−116, University of Illinois at Urbana-Champaign, Urbana.

(50) Sun, A., Moore, T. W., Gunther, J. R., Kim, M., Rhoden, E., Du, Y., Fu, H., Snyder, J. P., and Katzenellenbogen, J. A. (2011) Discovering small-molecule estrogen receptor α/coactivator binding inhibitors: high-throughput screening, ligand development, and models for enhanced potency. *ChemMedChem 6*, 654−666.